Cyclopharm Discloses Final Director Interest as Heaney Exits Board

Cyclopharm Limited ( (AU:CYC) ) has issued an announcement.

Cyclopharm Limited has announced that director David James Heaney ceased to be a director on 8 May 2026, triggering a final disclosure of his interests in the company’s securities under ASX requirements. The notice records that Heaney, via Mount Melleray Pty Ltd as trustee for The Heaney Super Fund, holds 331,052 fully paid ordinary shares and has no additional relevant interests or contractual securities exposures disclosed at the time of his departure.

The announcement clarifies the extent of Heaney’s remaining shareholding as he exits the board, providing transparency for investors regarding insider ownership. This final interest notice helps maintain regulatory compliance and informs stakeholders about changes in the company’s governance profile, though it does not signal any broader strategic or operational shifts by Cyclopharm itself.

The most recent analyst rating on (AU:CYC) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.

More about Cyclopharm Limited

Cyclopharm Limited is an ASX-listed company, identified in the filing by its Australian Business Number, operating within the healthcare and medical sector. The company issues fully paid ordinary shares and is subject to Australian corporate and securities regulation, including disclosure of directors’ interests under ASX listing rules and the Corporations Act.

Average Trading Volume: 122,155

Technical Sentiment Signal: Sell

Current Market Cap: A$92.66M

See more insights into CYC stock on TipRanks’ Stock Analysis page.